The company is undergoing a phase of scaling up, pursuing a dual-track process: - Fundraising aimed, on the one hand, at industrializing the dopamine manufacturing process under anaerobic conditions and, on the other hand, at conducting the Phase III program designed to support the approval of the drug candidate in Europe and the United States as a priority.
Amount sought: €40 million dilutive and €10 million non-dilutive - actively seeking an industrial partner
Current series: Series A
Startup contact: veronique.foutel@inbrainpharma.com
Theme: Pharmaceuticals
Applications: Neurology, Parkinson's disease
Partnerships and awards: Awards: i-Lab 2018, Deeptech 2019, France 2030 “Première Usine” 2025, Hauts de France Feder-FSE +-FDJ regional program 2021-2027
Laboratory: TREAT Team UMR-S 1172, EA7365
Institutions: LILLE UNIVERSITY HOSPITAL / INSERM/ University of Lille
Intellectual property: a first patent on the method and a second patent on the product.
Technology
InBrain Pharma's therapeutic innovation consists of the continuous intracerebroventricular administration of dopamine under anaerobic conditions in patients with advanced refractory Parkinson's disease suffering from complications related to levodopa-based therapies.
Applications
Treatment of neurodegenerative diseases, particularly Parkinson's disease (PD).
Benefits
Anaerobic dopamine (A-dopamine) significantly reduces motor impairment in patients with advanced Parkinson's disease who have become refractory to levodopa-based therapies (Moreau et al., Nature Medicine 2025).
Maturity
Phase I/II clinical trial completed on September 30, 2025, including a 4.5-year long-term follow-up phase. Positive scientific advice from the EMA on the Phase III clinical trial.
For more information
Contact your dedicated advisor